ERG245
Product Specifications
UNSPSC Description
ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/erg245.html
Smiles
OC(CCC(C(C1=CC=C(Br)C=C1)=O)C2=CC=CC=C2)=O
Molecular Weight
347.20
References & Citations
[1]Lodi F, et al. BCAT1 inhibition affects CD8+ T cell activation, exhaustion, and tumoral immunity by altering iron homeostasis[J]. bioRxiv, 2023: 2023.02. 25.530034.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-159730/ERG245-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-159730/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
15162121 3 x 1.0μg DNA
CCBP2 CRISPRa sgRNA lentivector (set of three targets)(Human)
Ask
View Details 